Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem posted Q3 2026 net product revenue of $24.0 million, more than double the $11.2 million a year earlier, driven by strong refill growth for AVMAPKI FAKZYNJA CO-PACK. Lead pipeline asset VS-7375 showed a 41% confirmed ORR in 2L+ pancreatic cancer and 43% in 2L+ NSCLC, and Verastem reached FDA alignment on the Phase 3 TARGET-D 301 trial design in 1L mPDAC, expected to open by year-end. The October follow-on offering raised $250.0 million gross, bringing pro forma cash to $422.8 million and extending the runway into 1H 2028. Offsets: non-GAAP adjusted net loss widened to $72.8 million from $39.1 million on a 137% R&D ramp, and Michael P.
Key figures
- Revenue
- 24012000
- Revenue Yoy
- 114%
- Dcr pdac
- 86%
- Orr 3l crc
- 33% unconfirmed
- Rd expense
- 68806000
- Cash runway
- into 1H 2028
- Orr 2l pdac
- 41% confirmed (50% in 2L)
- Orr 2l nsclc
- 43% confirmed
- Pro forma cash
- 422800000
- Six month pfs pdac
- 67%
- Cash and investments
- 172801000
- Total operating expenses
- 99236000
- Non gaap adjusted net loss
- 72826000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.